Aclarion Begins Patient Enrollment in Clarity Trial for Nociscan

Aclarion (ACON) has begun patient enrollment for the Clarity trial to assess the clinical and financial benefits of Nociscan in spinal surgeries. The trial's internal interim results are expected in Q2 2026. Analysts forecast an average target price of $11,758.50 with a 172,819.12% upside from the current price of $6.80. The average brokerage recommendation is 2.0, indicating an "Outperform" status.

Aclarion Inc (ACON) has initiated patient enrollment for the Clarity trial, a pivotal study aimed at evaluating the clinical and financial benefits of Nociscan in spinal surgeries. The trial's first patient was enrolled at the Texas Back Institute, marking a significant milestone in the clinical validation process for Nociscan, a SaaS platform that utilizes MR Spectroscopy and AI technology to identify sources of chronic low back pain [2].

The Clarity trial will enroll 300 patients across multiple prestigious institutions, including Texas Back Institute, Johns Hopkins, Northwestern Medicine, and others. The randomized study will compare surgical outcomes between surgeons with and without access to Nociscan data. The primary endpoint measures changes in back pain at 12 months post-surgery [2].

Analysts forecast an average target price of $11,758.50 for Aclarion Inc (ACON), with a 172,819.12% upside from the current price of $6.80. The average brokerage recommendation is 2.0, indicating an "Outperform" status [1]. The company is expected to release internal interim results of the Clarity trial in the second quarter of 2026 [1].

The trial's methodology is robust, employing a 1:1 randomization ratio between surgeons blinded to Nociscan data versus those with access to it. This will directly measure whether Nociscan's biomarker analysis improves surgical outcomes [2]. Nociscan's technology addresses a significant challenge in spine care, offering an objective, non-invasive approach to a traditionally subjective diagnostic challenge [2].

The addressable market for Nociscan is substantial, with approximately 266 million people worldwide suffering from degenerative spine disease and low back pain. If the CLARITY trial demonstrates Nociscan's ability to improve surgical outcomes, it could establish a new standard of care in spine surgery patient selection [2].

Investors should note the extended timeline, with interim results not expected until Q2 2026. This enrollment represents just the beginning of a lengthy clinical validation process, and commercial impact would depend on positive trial results that are still approximately a year away [2].

References:
[1] https://www.gurufocus.com/news/2944363/aclarion-acon-begins-patient-enrollment-in-clarity-trial-for-nociscan--acon-stock-news?mod=news_archive&r=4bf001661e6fdd88d0cd7a5659ff9748
[2] https://www.stocktitan.net/news/ACON/first-patient-enrolled-in-aclarion-s-groundbreaking-clarity-fn7befvrglpa.html